A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
Brief description of study
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
Clinical Study Identifier: s23-00634
ClinicalTrials.gov Identifier: NCT05945823
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
